Document Detail

HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B.
MedLine Citation:
PMID:  11208440     Owner:  NLM     Status:  MEDLINE    
The prevalence of hepatitis B infection in population in Poland is low and averages 1-1.5%. However, it means that about 380,000 Poles constantly or temporarily replicate HBV. Chronic HBV infection is associated with increased risk of serious liver diseases and it is estimated that 25-40% of patients with chronic hepatitis B will die prematurely of cirrhosis or primary liver cancer. Up to the present, interferon-alpha (IFN-alpha), with low response rate between 25-55% and some limitations of therapy, has been the only available treatment for chronic hepatitis B. A favorable outcome of IFN-alpha therapy is associated with some prognostic factors, not accepted by all investigators, such as low level of HBV-DNA in serum. The aim of this study was to assess the efficacy of therapy with IFN-alpha 2b (Intron A), administered s.c. 5 MU x 3/week for 16 weeks, in 65 patients with chronic hepatitis B, divided into groups according to the baseline HBV-DNA level. Except for serum HBV-DNA level, there were no demographical and biochemical differences between all the treated groups. The patients were followed-up for 12 months. Sustained response (SR) to the therapy (defined as ALAT normalization, loss of detectable HBV-DNA, seroconversion HBeAg to anti-HBeAg and improvement in liver histology) was observed in 16 (57.14%) of patients in the group with HBVDNA level < 1000 pg/ml, in 6 (37.5%) with HBV-DNA level of 1001-3000 pg/ml, in 4 (28.57%) with HBV-DNA level of 3001-5000 pg/ml and only in 2 (28.57%) of patients in group with HBVDNA level > 5000 pg/ml. We conclude that IFN-alpha is particularly useful in therapy of patients with chronic hepatitis B with low levels of HBV-DNA. The baseline HBVDNA level < 1000 pg/ml in serum is the predictor of good response to IFN-alpha therapy.
K Simon; K Rotter; M Zalewska; A Gładysz
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Medical science monitor : international medical journal of experimental and clinical research     Volume:  6     ISSN:  1234-1010     ISO Abbreviation:  Med. Sci. Monit.     Publication Date:    2000 Sep-Oct
Date Detail:
Created Date:  2001-03-05     Completed Date:  2001-04-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9609063     Medline TA:  Med Sci Monit     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  971-5     Citation Subset:  IM    
Department of Clinic of Infectious Diseases, Medical University, ul. Koszarowa 5, 51-149 Wrocław, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA, Viral / blood*
Hepatitis B virus / isolation & purification*
Hepatitis B, Chronic / drug therapy*,  virology*
Interferon Alfa-2b / therapeutic use*
Middle Aged
Treatment Outcome
Reg. No./Substance:
0/DNA, Viral; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Next Document:  Reactivity of cerebral arteries after subarachnoid hemorrhage in rats after phosphoramidon administe...